NHS Approves Enhertu for Incurable Breast Cancer in England 2026

Women in England with incurable breast cancer will now have access to the life-extending drug Enhertu on the NHS, following successful price negotiations. This decision marks a significant victory for patients and advocacy groups who have campaigned for the treatment's availability.

What Is Enhertu and Who Qualifies?

Enhertu (trastuzumab deruxtecan) is a targeted therapy for HER2-low advanced breast cancer. Approximately 1,000 women per year in England with this specific type of incurable breast cancer will be eligible to receive the drug from Thursday. HER2-low breast cancer is characterized by low levels of the HER2 protein, which previously limited treatment options.

Clinical Trial Results

Clinical trials have demonstrated that Enhertu almost doubled median progression-free survival compared to standard chemotherapy, extending it from 5.1 months to 9.9 months. Median overall survival was 23.4 months for those on Enhertu, versus 16.8 months for those not on it—a gain of 6.6 months. These results underscore the drug's potential to provide precious extra time with loved ones.

NHS Approval and Cost-Effectiveness

The National Institute for Health and Care Excellence (NICE) initially rejected Enhertu in July 2024 due to its high cost. However, after negotiations between ministers and the drug's manufacturer, a deal was reached, leading NICE to recommend it for routine use. This reversal highlights the importance of making life-extending treatments accessible despite financial challenges.

Reactions from Advocacy Groups

Claire Rowney, chief executive of Breast Cancer Now, called it a "momentous day" for thousands who will now have the opportunity to gain precious time with loved ones. The decision is a testament to persistent advocacy and the urgent need for effective treatments for incurable cancers.

Key Takeaways

• Enhertu is now available on the NHS for HER2-low advanced breast cancer.
• About 1,000 women annually will benefit from this life-extending drug.
• Clinical trials show significant improvements in progression-free and overall survival.
• NICE reversed its initial rejection after successful price negotiations.

Comparing Enhertu to Standard Chemotherapy

FAQ

Best Products We’ve Tested and Rated

Our testing team has hands-on reviews of brand mini split, car battery charger, baby detergent, pool cleaner, and wrist brace carpal tunnel. Every option below was compared across price, build quality, and real-world performance, with honest pros and cons. We update these guides regularly as new models arrive, so the recommendations stay current.

Our testing team has hands-on reviews of reclining sofa, essential oil brands, teacher bags, trolling rods salt water, and portable basketball hoop. Every option below was compared across price, build quality, and real-world performance, with honest pros and cons. We update these guides regularly as new models arrive, so the recommendations stay current.